KRAS and neoplasm: Zhang et al reported that the overexpression of miR‐134 significantly inhibited cell proliferation and xenograft tumour development; furthermore, they suggested a mechanism whereby miR‐134 plays an antitumour role by down‐regulating the expression of KRAS and STAT5B.14